Health
Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
Artur Widak | Nurphoto | Getty Images Shares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock has […]
Read More
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because […]
Read More
AI, wearables and more — these markets are booming as the world ages. The pros share 4 stock picks
The world is aging rapidly, and there are more and more ways to invest in this theme. Shams Afzal, managing director at Carnegie Investment Counsel, noted that 17% of the U.S. population is now over the age of 65, and that proportion is expected to grow higher. And the demographics of that age group is […]
Read More
Obesity and Alzheimer's drugs pack one-two punch to power Eli Lilly higher in 2024
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer […]
Read More
Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo Nordisk and Eli Lilly might use the same term for the returns they’ve realized over the past year. U.S.-listed shares of Novo Nordisk, the maker […]
Read More
Asia’s year in review: Who had it good — and who had it bad — in 2023
Curtis S. Chin, a former U.S. ambassador to the Asian Development Bank, is managing director of advisory firm RiverPeak Group. Jose B. Collazo is an analyst focusing on the Indo-Pacific region. Follow them on X at @CurtisSChin and @JoseBCollazo. As 2023 comes to a close, we take a look at the year that was in […]
Read More
CDC director says U.S. isn't yet near peak Covid or flu levels for the season
Winter officially begins Thursday, and with the cold season comes an expected rise in rates of flu and Covid, said Dr. Mandy Cohen, the director of the Centers for Disease Control and Prevention. The U.S. is seeing a “sharp increase” in flu levels right now, particularly in the south, Cohen said Wednesday in an interview. […]
Read More
Weight loss drugs, Alzheimer's treatments and gene editing: Enormous firsts defined 2023 in pharma
Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts that will shape the pharmaceutical industry in 2024 and beyond. The weight loss drug market transformed into the pharmaceutical industry’s newest gold rush this year, as demand for costly but highly effective treatments from Novo Nordisk […]
Read More
Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
Jim Cramer ran through all 33 stocks in his Charitable Trust portfolio during the December edition of the CNBC Investing Club’s Monthly Meeting. Source
Read More
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. […]
Read More